Your browser doesn't support javascript.
Genomic evidence of SARS-CoV-2 reinfection in the Republic of Korea.
Park, Ae Kyung; Rhee, Jee Eun; Kim, Il-Hwan; Kim, Heui Man; Lee, Hyeokjin; Kim, Jeong-Ah; Lee, Chae Young; Lee, Nam-Joo; Woo, SangHee; Lee, Jaehee; No, Jin Sun; Rhie, Gi-Eun; Wang, Seong Jin; Lee, Sang-Eun; Park, Young Joon; Park, Gemma; Kim, Jung Yeon; Gwack, Jin; Yoo, Cheon-Kwon; Kim, Eun-Jin.
  • Park AK; Division of Emerging Infectious Diseases, Bureau of Infectious Diseases Diagnosis Control, Korea Disease Control and Prevention Agency (KDCA), Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, Republic of Korea.
  • Rhee JE; Division of Emerging Infectious Diseases, Bureau of Infectious Diseases Diagnosis Control, Korea Disease Control and Prevention Agency (KDCA), Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, Republic of Korea.
  • Kim IH; Division of Emerging Infectious Diseases, Bureau of Infectious Diseases Diagnosis Control, Korea Disease Control and Prevention Agency (KDCA), Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, Republic of Korea.
  • Kim HM; Division of Emerging Infectious Diseases, Bureau of Infectious Diseases Diagnosis Control, Korea Disease Control and Prevention Agency (KDCA), Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, Republic of Korea.
  • Lee H; Division of Emerging Infectious Diseases, Bureau of Infectious Diseases Diagnosis Control, Korea Disease Control and Prevention Agency (KDCA), Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, Republic of Korea.
  • Kim JA; Division of Emerging Infectious Diseases, Bureau of Infectious Diseases Diagnosis Control, Korea Disease Control and Prevention Agency (KDCA), Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, Republic of Korea.
  • Lee CY; Division of Emerging Infectious Diseases, Bureau of Infectious Diseases Diagnosis Control, Korea Disease Control and Prevention Agency (KDCA), Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, Republic of Korea.
  • Lee NJ; Division of Emerging Infectious Diseases, Bureau of Infectious Diseases Diagnosis Control, Korea Disease Control and Prevention Agency (KDCA), Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, Republic of Korea.
  • Woo S; Division of Emerging Infectious Diseases, Bureau of Infectious Diseases Diagnosis Control, Korea Disease Control and Prevention Agency (KDCA), Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, Republic of Korea.
  • Lee J; Division of Emerging Infectious Diseases, Bureau of Infectious Diseases Diagnosis Control, Korea Disease Control and Prevention Agency (KDCA), Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, Republic of Korea.
  • No JS; Division of High-Risk Pathogens, Bureau of Infectious Disease Diagnosis Control, Korea Disease Control and Prevention Agency (KDCA), Cheongju-si, Chungcheongbuk-do, Republic of Korea.
  • Rhie GE; Division of High-Risk Pathogens, Bureau of Infectious Disease Diagnosis Control, Korea Disease Control and Prevention Agency (KDCA), Cheongju-si, Chungcheongbuk-do, Republic of Korea.
  • Wang SJ; Epidemiological Investigation Team, Epidemiological Investigation and Analysis Task Force, Korea Disease Control and Prevention Agency (KDCA), Cheongju-si, Chungcheongbuk-do, Republic of Korea.
  • Lee SE; Epidemiological Investigation Team, Epidemiological Investigation and Analysis Task Force, Korea Disease Control and Prevention Agency (KDCA), Cheongju-si, Chungcheongbuk-do, Republic of Korea.
  • Park YJ; Epidemiological Investigation Team, Epidemiological Investigation and Analysis Task Force, Korea Disease Control and Prevention Agency (KDCA), Cheongju-si, Chungcheongbuk-do, Republic of Korea.
  • Park G; Case and Guideline Management Team, Infection Prevention Support Team, Central Disease Control Headquarters, Korea Disease Control and Prevention Agency (KDCA), Cheongju-si, Chungcheongbuk-do, Republic of Korea.
  • Kim JY; Case and Guideline Management Team, Infection Prevention Support Team, Central Disease Control Headquarters, Korea Disease Control and Prevention Agency (KDCA), Cheongju-si, Chungcheongbuk-do, Republic of Korea.
  • Gwack J; Case and Guideline Management Team, Infection Prevention Support Team, Central Disease Control Headquarters, Korea Disease Control and Prevention Agency (KDCA), Cheongju-si, Chungcheongbuk-do, Republic of Korea.
  • Yoo CK; Bureau of Infectious Diseases Diagnosis Control, Korea Disease Control and Prevention Agency (KDCA), Cheongju-si, Chungcheongbuk-do, Republic of Korea.
  • Kim EJ; Division of Emerging Infectious Diseases, Bureau of Infectious Diseases Diagnosis Control, Korea Disease Control and Prevention Agency (KDCA), Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, Republic of Korea.
J Med Virol ; 94(4): 1717-1722, 2022 04.
Article in English | MEDLINE | ID: covidwho-1718401
ABSTRACT
As the coronavirus disease 2019 (COVID-19) pandemic continues, reinfection is likely to become increasingly common. However, confirming COVID-19 reinfection is difficult because it requires whole-genome sequencing of both infections to identify the degrees of genetic differences. Since the first reported case of reinfection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the Republic of Korea in April 2020, four additional cases were classified as suspected reinfection cases. We performed whole-genome sequencing of viral RNA extracted from swabs obtained at the initial infection and reinfection stages of these four suspected cases. The interval between initial infection and reinfection of all four suspected cases was more than 3 months. All four patients were young (10-29 years), and they displayed mild symptoms or were asymptomatic during the initial infection and reinfection episodes. The analysis of genome sequences combined with the epidemiological results revealed that only two of the four cases were confirmed as reinfection, and both were reinfected with the Epsilon variant. Due to the prolonged COVID-19 pandemic, the possibility of reinfections with SARS-CoV-2 variants is increasing, as reported in our study. Therefore, continuous monitoring of cases is necessary.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Genome, Viral / Reinfection / SARS-CoV-2 / COVID-19 Type of study: Observational study / Randomized controlled trials Topics: Variants Limits: Adolescent / Adult / Female / Humans / Male Country/Region as subject: Asia Language: English Journal: J Med Virol Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Genome, Viral / Reinfection / SARS-CoV-2 / COVID-19 Type of study: Observational study / Randomized controlled trials Topics: Variants Limits: Adolescent / Adult / Female / Humans / Male Country/Region as subject: Asia Language: English Journal: J Med Virol Year: 2022 Document Type: Article